Sjogren's Syndrome Clinical Trial
Official title:
An Open-Label, One Arm, Phase I Safety Study of Anti-CD20 Antibody (Rituximab, Rituxan) Therapy in the Treatment of Primary Sjogren's Syndrome
Verified date | October 2017 |
Source | National Institute of Allergy and Infectious Diseases (NIAID) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the safety of the anti-CD20 antibody rituximab in treating patients with Sjogren's syndrome (SS). Rituximab is a laboratory-made antibody currently used to treat some kinds of lymphoma. Rituximab may also help people with SS, a disease of the immune system. However, the safety of rituximab in SS patients must first be established.
Status | Completed |
Enrollment | 12 |
Est. completion date | August 2009 |
Est. primary completion date | August 2006 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Weighs at least 40 kg (88.2 lbs) - Meets European criteria proposed by the American-European Consensus Group for primary Sjogren's syndrome - Has 1 or more of the following symptoms of Sjogren's syndrome: fatigue; joint pain; peripheral neuropathy; interstitial lung disease; leukocytoclastic vasculitis; renal tubular acidosis; interstitial nephritis; severe parotid swelling; or other extraglandular manifestations causing organ system dysfunction - Agrees to use acceptable methods of contraception during the study and for 12 months after the end of treatment Exclusion Criteria: - Active infection - Chronic or persistent infection which might be worsened by immunosuppressive treatment (e.g., HIV, hepatitis B or C, tuberculosis [TB]) - Known coronary artery disease, significant cardiac arrhythmias, or severe congestive heart failure (New York Heart Association class III or IV) - Current use of anticoagulants - Prior use of rituximab - Cyclophosphamide treatment within 24 weeks prior to screening - Certain medications that may cause dry mouth - Cytotoxic therapy with azathioprine, cyclosporine, methotrexate, or mycophenolate mofetil within 4 weeks prior to screening - Etanercept within 4 weeks prior to screening - Adalumimab within 8 weeks prior to screening - Infliximab within 12 weeks prior to screening - Prednisone at greater than 10 mg/day within 2 weeks prior to screening. Patients who have their steroid doses tapered to 10 mg/day or less within 2 weeks of screening are not excluded. - Definitive diagnosis of another autoimmune rheumatologic disease (e.g., systemic lupus erythematosus, scleroderma, rheumatoid arthritis) - History of alcohol or substance abuse - History of immunoglobulin E (IgE)-mediated or non-IgE-mediated hypersensitivity - Known anaphylaxis to mouse-derived proteins - History of head and neck radiation therapy - History of sarcoidosis (inflammation of unknown cause occurring in the lymph nodes, lungs, liver, eyes, skin, or other tissues) - History of graft-versus-host disease - History of cancer. Patients who have had resected basal or major squamous cell carcinoma, cervical dysplasia, or in situ cervical cancer Grade I within the last 5 years prior to study entry are not excluded. - History of positive PPD without documentation of treatment for TB infection or chemoprophylaxis for TB exposure - Live vaccines within the 3 months prior to study entry - Severe pulmonary disease. Patients who do not have undue fatigue or dyspnea following ordinary physical activity are not excluded. - Psychiatric disorder precluding informed consent - Inability or unwillingness to follow study requirements - Any current condition or treatment that, in the opinion of the investigator, may interfere with the study - Pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence |
United States,
Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003 Apr;14(4):520-35. Review. Erratum in: Ann Oncol. 2003 Jun;14(6):967. — View Citation
Cheson BD. Rituximab: clinical development and future directions. Expert Opin Biol Ther. 2002 Jan;2(1):97-110. Review. — View Citation
Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol. 2004 May;16(3):180-5. Review. — View Citation
St Clair EW, Levesque MC, Prak ET, Vivino FB, Alappatt CJ, Spychala ME, Wedgwood J, McNamara J, Moser Sivils KL, Fisher L, Cohen P; Autoimmunity Centers of Excellence. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mech — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Count of Participants with Rituximab Related Grade 3 or higher AEs | The study site will grade the severity of adverse events (AEs) experienced by the study participants according to the criteria set forth in the National Cancer Institute's Common Toxicity Criteria for Adverse Events Version 3.0 (published June 10, 2003). | Throughout study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT04968912 -
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
|
Phase 2 | |
Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
Completed |
NCT00809003 -
Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease
|
N/A | |
Completed |
NCT00023491 -
Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells
|
N/A | |
Completed |
NCT05005806 -
Fish Oil (Omega 3 ) in Sjogren's Syndrome
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT03436576 -
Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye
|
Phase 3 | |
Terminated |
NCT04143841 -
Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease
|
N/A | |
Completed |
NCT03611283 -
Topical Management of Xerostomia With Dry Mouth Products
|
N/A | |
Recruiting |
NCT06104124 -
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
|
Phase 3 | |
Recruiting |
NCT05115487 -
Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
|
||
Recruiting |
NCT06437652 -
An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
|
||
Recruiting |
NCT05383677 -
Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT03938207 -
Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
|
||
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Completed |
NCT04546542 -
Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
|
||
Recruiting |
NCT05085431 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
|
Early Phase 1 | |
Completed |
NCT00565526 -
Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
|
||
Completed |
NCT01369589 -
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
|
Phase 1/Phase 2 | |
Completed |
NCT00001953 -
The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers
|
N/A |